Amygdalin inhibits renal fibrosis in chronic kidney disease

  • Authors:
    • Junqi Guo
    • Weizheng Wu
    • Mingxiong Sheng
    • Shunliang Yang
    • Jianming Tan
  • View Affiliations

  • Published online on: March 22, 2013     https://doi.org/10.3892/mmr.2013.1391
  • Pages: 1453-1457
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Renal interstitial fibrosis is a common outcome of chronic renal diseases. Amygdalin is one of a number of nitrilosides, the natural cyanide‑containing substances abundant in the seeds of plants of the prunasin family that are used to treat cancer and relieve pain. However, whether amygdalin inhibits the progression of renal fibrosis or not remains unknown. The present study aimed to assess the therapeutic potential of amygdalin by investigating its effect and potential mechanism on the activation of renal interstitial fibroblast cells and renal fibrosis in rat unilateral ureteral obstruction (UUO). Treatment of the cultured renal interstitial fibroblasts with amygdalin inhibited their proliferation and the production of transforming growth factor (TGF)‑β1. In the rat model of obstructive nephropathy, following ureteral obstruction, the administration of amygdalin immediately eliminated the extracellular matrix accumulation and alleviated the renal injury on the 21st day. Collectively, amygdalin attenuated kidney fibroblast (KFB) activation and rat renal interstitial fibrosis. These results indicate that amygdalin is a potent antifibrotic agent that may have therapeutic potential for patients with fibrotic kidney diseases.

References

1 

Noronha IL, Fujihara CK and Zatz R: The inflammatory component in progressive renal disease - are interventions possible? Nephrol Dial Transplant. 17:363–368. 2002. View Article : Google Scholar : PubMed/NCBI

2 

Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol. 214:199–210. 2008. View Article : Google Scholar

3 

Neilson EG: Mechanisms of disease: Fibroblasts - a new look at an old problem. Nat Clin Pract Nephrol. 2:101–108. 2006. View Article : Google Scholar : PubMed/NCBI

4 

Boor P, Ostendorf T and Floege J: Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. 6:643–656. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Liu Y: Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 69:213–217. 2006. View Article : Google Scholar : PubMed/NCBI

6 

Eddy AA: Molecular basis of renal fibrosis. Pediatr Nephrol. 15:290–301. 2000. View Article : Google Scholar

7 

Böttinger EP and Bitzer M: TGF-beta signaling in renal disease. J Am Soc Nephrol. 13:2600–2610. 2002.

8 

Fujihara CK, Malheiros DM, Zatz R and Noronha IL: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int. 54:1510–1519. 1998. View Article : Google Scholar : PubMed/NCBI

9 

Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345:851–860. 2001. View Article : Google Scholar

10 

Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345:861–869. 2001. View Article : Google Scholar

11 

Chang HK, Yang HY, Lee TH, et al: Armeniacae semen extract suppresses lipopolysaccharide-induced expressions of cyclooxygenase (correction of cycloosygenase)-2 and inducible nitric oxide synthase in mouse BV2 microglial cells. Biol Pharm Bull. 28:449–454. 2005. View Article : Google Scholar

12 

Fukuda T, Ito H, Mukainaka T, Tokuda H, Nishino H and Yoshida T: Anti-tumor promoting effect of glycosides from Prunus persica seeds. Biol Pharm Bull. 26:271–273. 2003. View Article : Google Scholar : PubMed/NCBI

13 

Liu N, Tolbert E, Pang M, Ponnusamy M, Yan H and Zhuang S: Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol. 22:1064–1075. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Robertson H, Ali S, McDonnell BJ, Burt AD and Kirby JA: Chronic renal allograft dysfunction: the role of T cell-mediated tubular epithelial to mesenchymal cell transition. J Am Soc Nephrol. 15:390–397. 2004. View Article : Google Scholar : PubMed/NCBI

15 

Chang HK, Shin MS, Yang HY, et al: Amygdalin induces apoptosis through regulation of Bax and Bcl-2 expressions in human DU145 and LNCaP prostate cancer cells. Biol Pharm Bull. 29:1597–1602. 2006. View Article : Google Scholar : PubMed/NCBI

16 

Vongwiwatana A, Tasanarong A, Rayner DC, Melk A and Halloran PF: Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant. 5:1367–1374. 2005. View Article : Google Scholar : PubMed/NCBI

17 

Zeisberg M, Hanai J, Sugimoto H, et al: BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 9:964–968. 2003. View Article : Google Scholar : PubMed/NCBI

18 

Wang W, Huang XR, Li AG, et al: Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol. 16:1371–1383. 2005. View Article : Google Scholar : PubMed/NCBI

19 

Shihab FS, Bennett WM, Yi H and Andoh TF: Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant. 2:111–119. 2002. View Article : Google Scholar

20 

Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol. 15:1–12. 2004. View Article : Google Scholar

21 

Heeg MH, Koziolek MJ, Vasko R, et al: The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int. 68:96–109. 2005. View Article : Google Scholar : PubMed/NCBI

22 

Satoh S, Yamaguchi T, Hitomi A, et al: Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol. 455:169–174. 2002. View Article : Google Scholar : PubMed/NCBI

23 

Strutz F and Müller GA: Renal fibrosis and the origin of the renal fibroblast. Nephrol Dial Transplant. 21:3368–3370. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

May 2013
Volume 7 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Guo, J., Wu, W., Sheng, M., Yang, S., & Tan, J. (2013). Amygdalin inhibits renal fibrosis in chronic kidney disease. Molecular Medicine Reports, 7, 1453-1457. https://doi.org/10.3892/mmr.2013.1391
MLA
Guo, J., Wu, W., Sheng, M., Yang, S., Tan, J."Amygdalin inhibits renal fibrosis in chronic kidney disease". Molecular Medicine Reports 7.5 (2013): 1453-1457.
Chicago
Guo, J., Wu, W., Sheng, M., Yang, S., Tan, J."Amygdalin inhibits renal fibrosis in chronic kidney disease". Molecular Medicine Reports 7, no. 5 (2013): 1453-1457. https://doi.org/10.3892/mmr.2013.1391